Lee Ainslie Alkermes Plc. Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$21.47 - $32.08 $593,731 - $887,140	-27,654 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $135,966 - $186,932	5,818 Added 26.64%	27,654 $853,000
Q2 2021 Aug 16, 2021	SELL	$18.78 - $25.15 $191,969 - $257,083	-10,222 Reduced 31.89%	21,836 $535,000
Q1 2021 May 17, 2021	SELL	$18.21 - $23.2 $170,736 - $217,523	-9,376 Reduced 22.63%	32,058 $599,000
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $637,669 - $915,691	41,434 New	41,434 $827,000
Q2 2020 Aug 14, 2020	SELL	$13.31 - $19.41 $33.2 Million - $48.4 Million	-2,494,384 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$13.06 - $21.24 $32.6 Million - $53 Million	2,494,384 New	2,494,384 $36 Million

361

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.84B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.